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The Development of Small Animal Models for Zika Virus Vaccine Efficacy
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Zika virus (ZIKV) is a mosquito-borne flavivirus serologi-
cally grouped within the family Flaviviridae, which was ini-
tially isolated from a febrile sentinel monkey in the Zika
Forest of Uganda in 1947. Subsequent genetic analyses have
demonstrated the presence of two distinctive African and
Asian viral genotypes. After years of being associated only
with sporadic human illness, the first outbreak of ZIKV dis-
ease was reported in 2007, on the island of Yap in the Fed-
erated States of Micronesia (with 49 laboratory confirmed
cases documented).1 In subsequent years, ZIKV was associ-
ated with outbreaks in French Polynesia and then in the
South Pacific Islands of New Caledonia and Easter Island,
before disease being identified in Brazil in early 2015.
Although the majority of human ZIKV infections have been
found to result in asymptomatic or mild illness,1 the recent
identification of an association of ZIKV infection during
pregnancy with an increase in the incidence of microcephaly
in neonates,2 as well as the development of Guillain–Barré
syndrome resulted in the World Health Organization’s decla-
ration that the ZIKV outbreak constituted a “Public Health
Emergency of International Concern.”3 The unprecedented
geographic expansion of the virus, with up to 1.3 million esti-
mated human infections as of December 2015,4 its sexual
transmission potential, and its severe pathogenic effects in
fetuses (microcephaly, ocular malformations) have empha-
sized the critical need for available vaccines and antiviral
therapies, as well as an improved understanding of the path-
ological mechanisms that result in human disease after infec-
tion with this virus.
In this issue of the American Journal of Tropical Medicine
and Hygiene, Rossi and others5 describe preliminary experi-
ments that have identified murine models of ZIKV patho-
genesis. This work explores the pathological response of
type I interferon receptor knockout mice (A129) as well
as type I and type II interferon receptor knockout mice
(AG129) to peripheral challenge with a low-passage Asian
strain of ZIKV that was isolated from Cambodia in 2010.
A129 mice that were unable to respond to interferon-alpha
and -beta signaling manifested high viremia and demon-
strated an age-dependent susceptibility to disease. Three
week-old mice succumbed to infection and developed high
viremia (> 7 log10 plaque-forming units/mL sera), whereas
older mice exhibited less mortality and lower viremias. Simi-
larly, 3-week-old AG129 mice, unable to respond to type I
and II interferon signaling, were inoculated with the same
ZIKV strain, and demonstrated mortality after intraperitoneal
or intradermal inoculation. Three week-old A129 and AG129
mice succumbed within 7 days of inoculation, with notable
neurological involvement and subsequent identification of
virus in brain tissue. In contrast, immune-competent mice
peripherally challenged with the same ZIKV strain failed to
manifest viremia or demonstrate any signs of morbidity.
Most importantly, these immunocompromised mouse
models demonstrated disease and viremia after infection
with a low-passage ZIKV strain, negating the necessity for
passage adaptation for the elicitation of virulence. Previous
attempts to develop ZIKV murine models involved the serial
passage of the prototype strain in mice,6 complicating the
assessment of the effects of passage on virulence. Further-
more, passage adaptation can alter the antigenicity of the
resultant virus, thus obscuring any assessment of immuniza-
tion with a circulating strain of ZIKV from which a candi-
date vaccine is likely to be generated. Although the authors
have not directly assessed these models for susceptibility to
the specific Asian genotype viruses currently associated with
the ongoing outbreak, this work has set the stage for these
assessments, and serves as an initial, significant step toward
developing tools to assess the safety, immunogenicity, and pro-
tective efficacy of ZIKV vaccines under development. Although
the use of immunocompromised murine models negates the
direct assessment of the role of interferon response elements in
the disease process, this communication provides an experi-
mental framework that may be highly useful for the assessment
of host and virological factors involved in intrauterine and
sexual transmission of ZIKV, in addition to serving as a vaccine
challenge model. The authors did not assess specific tissues of
the female reproductive tract; however, robust viral replication
was observed in the testes of both A129 and AG129 mice, indi-
cating the potential appropriateness of these models for
assessing potential mechanisms for sexual transmission.
Data from nonhuman primate studies with ZIKV that
have been provided online (https://zika.labkey.com/project/
OConnor/ZIKV-001/begin.view) in a real-time manner have
demonstrated viral replication of a ZIKV isolate from
French Polynesia. However, the development of a small
animal model for initial assessment of the safety, immuno-
genicity, and protective efficacy of candidate vaccines will
facilitate the much broader screening of potential vaccine
candidates. A more thorough initial stage screening in a
rodent model will likely provide more viable candidates for
nonhuman primate testing and subsequent human clinical tri-
als. Although the ultimate utility of these two mouse models
for recapitulating the pathogenic potential of different ZIKV
strains for eliciting disease in humans is currently unknown,
this study ushers an important initial advance toward that
end, and it probably offers critical initial models for assessing
first-generation ZIKV vaccines.
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